| |
| |
|
| Insider
Information: |
Mcintyre Gail Frances |
| Relationship: |
CEO and President, Dir... |
| City: |
Morrisville |
| State: |
NC |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
65,490 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$2,626 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
65,490 |
|
|
| Total
Value |
$2,626 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
| Percentage
Gain/Loss : |
 -46.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Furiex Pharmaceuticals, Inc. |
FURX |
Senior Vice President-... |
2014-07-02 |
0 |
2011-11-17 |
0 |
Premium* |
|
|
Aravive Inc |
ARAV |
CEO and President, Dir... |
2022-10-24 |
65,490 |
2020-12-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
16 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARAV |
Aravive Inc |
CEO and President |
• • – |
2022-10-24 |
4 |
A |
$0.92 |
$49,999 |
D/D |
54,353 |
65,490 |
0 |
- |
|
| ARAV |
Aravive Inc |
CEO and President |
• • – |
2021-06-29 |
4 |
B |
$5.35 |
$5,345 |
D/D |
1,000 |
11,137 |
2.81 |
% |
|
| ARAV |
Aravive Inc |
CEO and President |
• • – |
2020-12-04 |
4 |
B |
$5.77 |
$46,160 |
D/D |
8,000 |
10,137 |
2.81 |
% |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-07-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,318) |
0 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-06-17 |
4 |
S |
$105.00 |
$840,840 |
D/D |
(8,008) |
24,318 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-06-17 |
4 |
OE |
$13.16 |
$105,385 |
D/D |
8,008 |
32,326 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-06-16 |
4 |
S |
$105.00 |
$6,977,591 |
D/D |
(66,449) |
24,318 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-06-16 |
4 |
OE |
$9.11 |
$738,890 |
D/D |
62,645 |
28,035 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-06-10 |
4 |
S |
$104.58 |
$182,597 |
D/D |
(1,746) |
28,122 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2014-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
29,868 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2013-07-19 |
4/A |
AS |
$40.00 |
$800,000 |
D/D |
(20,000) |
17,868 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2013-07-19 |
4 |
AS |
$40.00 |
$423,240 |
D/D |
(10,581) |
17,868 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2013-07-19 |
4 |
D |
$40.00 |
$376,760 |
D/D |
(9,419) |
28,449 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2013-07-19 |
4 |
OE |
$9.11 |
$182,200 |
D/D |
20,000 |
37,868 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• • – |
2013-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
11,100 |
17,868 |
0 |
- |
|
| FURX |
Furiex Pharmaceuticals, I... |
Senior Vice President-Research |
• – – |
2011-11-17 |
4 |
B |
$16.89 |
$109,785 |
D/D |
6,500 |
6,768 |
2.74 |
- |
|
16 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
